Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Institute of Medical Immunology, Charité Universitaetsmedizin Berlin, Berlin, Germany.
Front Immunol. 2022 May 24;13:891564. doi: 10.3389/fimmu.2022.891564. eCollection 2022.
Transplant centers around the world have been using extended criteria donors to remedy the ongoing demand for lung transplantation. With a rapidly aging population, older donors are increasingly considered. Donor age, at the same time has been linked to higher rates of lung ischemia reperfusion injury (IRI). This process of acute, sterile inflammation occurring upon reperfusion is a key driver of primary graft dysfunction (PGD) leading to inferior short- and long-term survival. Understanding and improving the condition of older lungs is thus critical to optimize outcomes. Notably, lung perfusion (EVLP) seems to have the potential of reconditioning ischemic lungs through perfusing and ventilation. Here, we aim to delineate mechanisms driving lung IRI and review both experimental and clinical data on the effects of aging in augmenting the consequences of IRI and PGD in lung transplantation.
世界各地的移植中心一直在使用扩展标准供体来解决肺移植的持续需求。随着人口的迅速老龄化,越来越多的老年供体被考虑。同时,供体年龄与更高的肺缺血再灌注损伤(IRI)发生率有关。再灌注时发生的这种急性无菌性炎症过程是导致原发性移植物功能障碍(PGD)的关键因素,导致短期和长期生存质量下降。因此,了解和改善老年肺部的状况对于优化结果至关重要。值得注意的是,肺灌注(EVLP)似乎通过灌注和通气有潜力使缺血肺再复康。在这里,我们旨在阐明驱动肺IRI 的机制,并回顾关于衰老在增强肺移植中IRI 和 PGD 后果的实验和临床数据。